Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Insight Molecular Diagnostics Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- +6 vs. Q3 2024
- Shares held
- 8.42M
- +1.25M (+17.4%) vs. Q3 2024
- Total value
- $20.0M
- −$395.2K (−1.9%) vs. Q3 2024
- New holders
- 6
- 9 more added
- Sold out
- 0
- 6 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IMDX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 40 | $108.9M |
| Q1 2026 | 41 | $62.1M |
| Q4 2025 | 35 | $124.9M |
| Q3 2025 | 27 | $54.1M |
| Q2 2025 | 30 | $48.9M |
| Q1 2025 | 30 | $49.2M |
| Q4 2024 | 27 | $20.0M |
| Q3 2024 | 21 | $20.4M |
| Q2 2024 | 23 | $21.1M |
| Q1 2024 | 25 | $12.8M |
| Q4 2023 | 26 | $11.1M |
| Q3 2023 | 30 | $14.3M |
| Q2 2023 | 47 | $21.1M |
| Q1 2023 | 52 | $19.7M |
| Q4 2022 | 59 | $19.5M |
| Q3 2022 | 65 | $48.3M |
| Q2 2022 | 76 | $61.8M |
| Q1 2022 | 86 | $81.1M |
| Q4 2021 | 89 | $120.1M |
| Q3 2021 | 95 | $201.9M |
| Q2 2021 | 91 | $324.6M |
| Q1 2021 | 87 | $283.0M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Insight Molecular Diagnostics Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Danske Bank A/S | 1 | $2 | 0.00% | 00.0% | Unchanged |
| Albion Financial Group | 7 | $17 | 0.00% | 00.0% | Unchanged |
| Coppell Advisory Solutions LLC | 10 | $24 | 0.00% | 00.0% | Unchanged |
| Piscataqua Savings Bank | 25 | $59 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 182 | $431 | 0.00% | −898−83.1% | Reduced |
| SBI Securities Co., Ltd. | 185 | $440 | 0.00% | +185 | New |
| JPMorgan Chase & Co | 195 | $465 | 0.00% | +41+26.6% | Added |
| BNP Paribas Arbitrage, SA | 208 | $495 | 0.00% | +208 | New |
| Bryn Mawr Trust Co | 250 | $595 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 436 | $1.04K | 0.00% | +24+5.8% | Added |
| Lee Danner & Bass Inc | 1,388 | $3.30K | 0.00% | +1,388 | New |
| UBS Group AG | 2,714 | $6.46K | 0.00% | +1,879+225.0% | Added |
| Tower Research Capital LLC (TRC) | 4,313 | $10.3K | 0.00% | +2,867+198.3% | Added |
| Ground Swell Capital, LLC | 10,915 | $26.0K | 0.06% | +10,915 | New |
| Two Sigma Securities, LLC | 13,215 | $31.5K | 0.01% | +13,215 | New |
| Northern Trust Corp | 17,333 | $41.3K | 0.00% | −13−0.1% | Reduced |
| State Street Corp | 19,554 | $46.5K | 0.00% | 00.0% | Unchanged |
| Defender Capital, LLC. | 47,078 | $112.0K | 0.04% | −12,275−20.7% | Reduced |
| FNY Investment Advisers, LLC | 49,377 | $117.0K | 0.06% | +6,481+15.1% | Added |
| Wealthedge Investment Advisors, LLC | 52,732 | $125.5K | 0.06% | +52,732 | New |
| Morgan Stanley | 61,708 | $146.9K | 0.00% | −10,581−14.6% | Reduced |
| BlackRock, Inc. | 79,957 | $190.3K | 0.00% | +124+0.2% | Added |
| Geode Capital Management, LLC | 137,069 | $326.3K | 0.00% | +33,089+31.8% | Added |
| Vanguard Group Inc | 242,206 | $576.5K | 0.00% | −3,182−1.3% | Reduced |
| Pura Vida Investments, LLC | 654,451 | $1.56M | 8.61% | +159,106+32.1% | Added |
| AWM Investment Company, Inc. | 775,804 | $1.85M | 0.22% | −321,371−29.3% | Reduced |
| Broadwood Capital Inc | 6,244,405 | $14.9M | 1.16% | +1,315,339+26.7% | Added |